IN2012DN02782A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02782A
IN2012DN02782A IN2782DEN2012A IN2012DN02782A IN 2012DN02782 A IN2012DN02782 A IN 2012DN02782A IN 2782DEN2012 A IN2782DEN2012 A IN 2782DEN2012A IN 2012DN02782 A IN2012DN02782 A IN 2012DN02782A
Authority
IN
India
Prior art keywords
antagonist
beta
patient
side effects
comprises administering
Prior art date
Application number
Inventor
Hiroshi Nagabukuro
Scott D Edmondson
Mary Struthers Sinharoy
William S Denney
Tara L Frenkl
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of IN2012DN02782A publication Critical patent/IN2012DN02782A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Described herein is an improved method of treating overactive bladder, wherein the method comprises administering to a patient in need thereof a beta 3 adrenergic receptor agonist, an antimuscarinic agent, and an optional selective M2 antagonist. Such combination therapy provides improved efficacy and/or reduced side effects.
IN2782DEN2012 2009-10-07 2010-09-27 IN2012DN02782A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24938609P 2009-10-07 2009-10-07
PCT/US2010/050328 WO2011043942A1 (en) 2009-10-07 2010-09-27 Combination therapy using a beta 3 adrenergic receptor agonist and an antimuscarinic agent

Publications (1)

Publication Number Publication Date
IN2012DN02782A true IN2012DN02782A (en) 2015-09-18

Family

ID=43857059

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2782DEN2012 IN2012DN02782A (en) 2009-10-07 2010-09-27

Country Status (15)

Country Link
US (1) US20120202819A1 (en)
EP (1) EP2485595A4 (en)
JP (1) JP5738871B2 (en)
KR (1) KR20120093859A (en)
CN (1) CN102638987A (en)
AU (1) AU2010303811B2 (en)
BR (1) BR112012007829A2 (en)
CA (1) CA2774992A1 (en)
IL (1) IL218756A0 (en)
IN (1) IN2012DN02782A (en)
MX (1) MX2012004134A (en)
NZ (1) NZ599233A (en)
RU (1) RU2012118668A (en)
WO (1) WO2011043942A1 (en)
ZA (1) ZA201202520B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
NZ607485A (en) * 2010-08-03 2015-04-24 Altherx Inc Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder
RU2671575C2 (en) * 2011-05-10 2018-11-02 Теравида, Инк. Appliance of solifenacin and saliva flow stimulators for the treatment of overactive bladder
US20150087832A1 (en) 2011-10-27 2015-03-26 Merck Sharp & Dohme, Corp. Process for making beta 3 agonists and intermediates
JP6088535B2 (en) 2011-10-27 2017-03-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Process for producing beta 3 agonists and intermediates
HK1204966A1 (en) * 2012-02-09 2015-12-11 Velicept Therapeutics, Inc. Combination of muscarinic receptor antagonists and beta- 3 adrenoceptor agonists for treating overactive bladder
ME03506B (en) 2013-03-15 2020-04-20 Merck Sharp & Dohme Process for preparing beta 3 agonists and intermediates
MX2016001030A (en) * 2013-07-23 2016-10-07 Allergan Inc Methods and compositions comprising desmopressin in combination with a beta-3 adrenergic receptor agonist.
KR20170097045A (en) 2014-11-20 2017-08-25 알레간 인코포레이티드 Methods and compositions comprising desmopressin in combination with an alpha-adrenergic receptor antagonist
US9956194B2 (en) 2014-12-03 2018-05-01 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
US20180360845A1 (en) * 2015-07-20 2018-12-20 Chase Pharmaceuticals Corporation Muscarinic combination of a selective m2-antagonist and a peripheral non-selective antagonist for treating hypocholinergic disorders
PL3365321T3 (en) 2015-10-23 2024-03-25 B3Ar Therapeutics, Inc. Solabegron zwitterion and uses thereof
WO2018039159A1 (en) * 2016-08-22 2018-03-01 Chase Pharmaceuticals Corporation Muscarinic m2-antagonist combination
US12102638B2 (en) 2017-06-06 2024-10-01 Urovant Sciences Gmbh Use of vibegron to treat overactive bladder
KR20250095747A (en) * 2017-06-06 2025-06-26 유로반트 사이언시즈 게엠베하 Dosing of vibegron for treatment of overactive bladder
CN111556753A (en) * 2017-12-21 2020-08-18 杏林制药株式会社 Therapeutic agent for frequent urination at night
TW202038963A (en) 2018-12-05 2020-11-01 瑞士商優洛凡特科學公司 Use of vibegron to treat overactive bladder symptoms in men with benign prostatic hyperplasia
CN115850286B (en) * 2022-12-05 2023-08-22 奥锐特药业(天津)有限公司 Vitamin Bei Gelong intermediate and preparation method thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2789076B1 (en) * 1999-02-02 2001-03-02 Synthelabo ALPHA-AZACYCLOMETHYL QUINOLEINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
GB2356197A (en) * 1999-10-12 2001-05-16 Merck & Co Inc Amide derivatives as beta 3 agonists
WO2003024483A1 (en) * 2001-09-11 2003-03-27 Fujisawa Pharmaceutical Co., Ltd. Potentiator for inhibitory effects on urinary frequency and urinary incontinence
TWI295669B (en) * 2002-10-30 2008-04-11 Theravance Inc Substituted 4-amino-1-(pyridylmethyl) piperidine and related compounds
US20040248979A1 (en) * 2003-06-03 2004-12-09 Dynogen Pharmaceuticals, Inc. Method of treating lower urinary tract disorders
EP1804778A1 (en) * 2004-10-18 2007-07-11 Boehringer Ingelheim International GmbH Use of a beta-3 agonist for treating complaints of the prostate and the lower urogenital tract
AU2008233232A1 (en) * 2007-03-29 2008-10-09 Merck Sharp & Dohme Corp. Combination therapy for the treatment-of lower urinary tract symptoms
PE20091825A1 (en) * 2008-04-04 2009-12-04 Merck & Co Inc HYDROXIMETHYL PYRROLIDINES AS AGONISTS OF THE BETA 3 ADRENERGIC RECEPTOR

Also Published As

Publication number Publication date
AU2010303811B2 (en) 2013-01-24
EP2485595A4 (en) 2014-03-12
CA2774992A1 (en) 2011-04-14
US20120202819A1 (en) 2012-08-09
NZ599233A (en) 2013-04-26
RU2012118668A (en) 2013-11-20
CN102638987A (en) 2012-08-15
BR112012007829A2 (en) 2015-09-22
AU2010303811A1 (en) 2012-04-19
EP2485595A1 (en) 2012-08-15
JP2013507363A (en) 2013-03-04
JP5738871B2 (en) 2015-06-24
ZA201202520B (en) 2012-12-27
WO2011043942A1 (en) 2011-04-14
IL218756A0 (en) 2012-06-28
KR20120093859A (en) 2012-08-23
MX2012004134A (en) 2012-05-08

Similar Documents

Publication Publication Date Title
IN2012DN02782A (en)
MX2011008450A (en) Agonists and antagonists of the s1p5 receptor, and methods of uses thereof.
BR112012025017A2 (en) methods to improve sleep quality.
AU2008232453A8 (en) Methods and compositions for reduction of side effects of therapeutic treatments
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
WO2009129432A3 (en) Alpha adrenergic receptor agonists for treatment of pain and/or inflammation
MX2009011898A (en) Compositions and methods for treating disorders associated with salt or fluid retention.
MX2010005331A (en) Compositions and methods for treating purpura.
MX337614B (en) Treatment of lupus nephritis using laquinimod.
EP4275752A3 (en) Treatment of addiction and impulse-control disorders using pde7 inhibitors
PH12013501244A1 (en) A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease
MY165160A (en) TREATMENT OF MYOCARDIAL INFARCTION USING TGF-ß ANTAGONISTS
PH12013500221A1 (en) Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder
MX2013003638A (en) Combination treatment for rosacea.
EP2490700A4 (en) A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof
WO2009052073A3 (en) Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists
MX341660B (en) Ghrelin receptor agonist for treatment of dyscrasia.
TN2011000457A1 (en) Method or system using biomarkers for the monitoring of a treatment
MX2009009332A (en) Mineralcorticoid receptor antagonists for the treatment of endometriosis.
MX2021011289A (en) Compositions comprising pkm2 modulators and methods of treatment using the same.
WO2009052075A3 (en) Method of treating motor disorders with alpha-2b adrenergic receptor agonists
WO2011109743A3 (en) Synergistic effects of combinations of buprenorphine and opioids for the treatment of pain
EP2566502A4 (en) Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection
MX2011012538A (en) Combination therapy for the treatment of multiple myeloma.
MX348723B (en) Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder.